Top Markets
#1 Akedo Akedo +128.53%
#2 TENDIES TENDIES +95.14%
#3 Threshold Network Threshold Network +43.87%
#4 Verus Coin Verus Coin +43.84%
#5 Mubarak Mubarak +28.64%
#6 Bitway Bitway +24.60%
#7 Palladium Network Palladium Network +22.70%
#8 Cash Cat Cash Cat +21.77%
#9 MultiversX MultiversX +18.70%
#10 Wrapped Aave Ethereum USDC Wrapped Aave Ethereum USDC +18.00%
Coin of the day
Akedo Akedo
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
Clasificación en acciones #17600
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Precio por acción
$8.16
Última sincronización: 2025-06-26
Capitalización bursátil
$234.57M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Regulus Therapeutics Inc. (RGLS)

Categoría

Healthcare
Ganancias de Regulus Therapeutics Inc. (RGLS)
Ganancias en Mar 2025 TTM: $-47.52M
Secondo gli ultimi rapporti finanziari di Regulus Therapeutics Inc., gli utili attuali della società sono $-47.52M. Nel 2023, la società ha registrato un utile di $-30.04M, una disminución en comparación con agli utili del 2022, che erano di $-28.32M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Regulus Therapeutics Inc. desde 2010 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
2026 (TTM) $-47.52M 2.51%
2024 $-46.36M 54.34%
2023 $-30.04M 6.05%
2022 $-28.32M 1.85%
2021 $-27.81M 76.78%
2020 $-15.73M -15.39%
2019 $-18.59M -61.78%
2018 $-48.65M -32.53%
2017 $-72.10M -11.90%
2016 $-81.84M 46.76%
2015 $-55.77M -1.61%
2014 $-56.68M 203.24%
2013 $-18.69M 7.31%
2012 $-17.42M 135.51%
2011 $-7.40M -52.56%
2010 $-15.59M 0.00%
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -11,199.91%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -4,204.73%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 6,395.94%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 8,351.24%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH